Hydrophilic biocompatible adhesive formulations and uses
This invention relates to the use of hydrophilic, biocompatible adhesives in drug delivery systems, wound dressings, bioelectrodes, and other systems in which hydrophilic, biocompatible adhesives are desirable. In particular, the invention relates to water-swellable, water-insoluble polymers that in combination render a composition adhesive upon contact with moisture, wherein a first water-swellable, water-insoluble polymer is cationic, a second water-swellable, water-insoluble polymer is anionic, and the polymers are ionically associated with each other to form a polymer matrix.
1 . A pharmaceutical composition comprising an admixture of:
a therapeutically effective amount of an active agent; and
at least two water-swellable, water-insoluble polymers that in combination render the composition adhesive upon contact with moisture, wherein a first water-swellable, water-insoluble polymer is cationic, a second water-swellable, water-insoluble polymer is anionic, and the polymers are ionically associated with each other to form a polymer matrix.
2 . The pharmaceutical composition of claim 1 , wherein at least one of the water-swellable, water-insoluble polymers is an acrylate-based polymer.
3 . The pharmaceutical composition of claim 2 , wherein the acrylate-based polymer is a polymer or copolymer of acrylic acid, methacrylic acid, acrylate, methyl acrylate, ethyl acrylate, methyl methacrylate, ethyl methacrylate, a dialkylaminoalkyl acrylate, a dialkylaminoalkyl methacrylate, a trialkylammonioalkyl acrylate, and/or a trialkylammonioalkyl methacrylate.
4 . The pharmaceutical composition of claim 3 , wherein the acrylate-based polymer is a polymer or copolymer of acrylic acid, methacrylic acid, methyl methacrylate, ethyl methacrylate, 2-dimethylaminoethyl methacrylate, and/or trimethylammonioethyl methacrylate chloride.
5 . The pharmaceutical composition of claim 1 , wherein the water-swellable, water-insoluble polymers are acrylate-based polymers.
6 . The pharmaceutical composition of claim 5 , wherein the acrylate-based polymers are polymers or copolymers of acrylic acid, methacrylic acid, acrylate, methyl acrylate, ethyl acrylate, methyl methacrylate, ethyl methacrylate, a dialkylaminoalkyl acrylate, a dialkylaminoalkyl methacrylate, a trialkylammonioalkyl acrylate, and/or a trialkylammonioalkyl methacrylate.
7 . The pharmaceutical composition of claim 6 , wherein the acrylate-based polymers are polymers or copolymers of acrylic acid, methacrylic acid, methyl methacrylate, ethyl methacrylate, 2-dimethylaminoethyl methacrylate, and/or trimethylammonioethyl methacrylate chloride.
8 . The pharmaceutical composition of claim 1 , wherein the cationic polymer is an acrylate-based polymer with pendant quaternary ammonium groups, and the anionic polymer is an ionized acrylic acid or methacrylic acid polymer.
9 . The pharmaceutical composition of claim 1 , further comprising 1.5 wt. % to 30 wt. % of a crosslinked hydrophilic polymer composition composed of (a) a covalently crosslinked hydrophilic polymer, and/or (b) a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding thereto.
10 . The pharmaceutical composition of claim 9 , wherein the crosslinked hydrophilic polymer composition represents up to about 10 wt. % of the pharmaceutical composition.
11 . The pharmaceutical composition of claim 9 , wherein the water-swellable, water-insoluble polymers represent at least 60 wt. % of the pharmaceutical composition.
12 . The pharmaceutical composition of claim 9 , wherein:
the hydrophilic polymer is selected from poly(N-vinyl lactams), poly(N-vinyl amides), poly(N-alkylacrylamides), polyvinyl alcohol, polyvinylamine, and copolymers thereof; and
the complementary oligomer is selected from polyalcohols, monomeric and oligomeric alkylene glycols, polyalkylene glycols, carboxyl-terminated polyalkylene glycols, amino-terminated polyalkylene glycols, ether alcohols, alkane diols, and carbonic diacids.
13 . The pharmaceutical composition of claim 10 , wherein:
the hydrophilic polymer is a poly(N-vinyl lactam); and
the complementary oligomer is selected from the group consisting of polyethylene glycol and carboxyl-terminated polyethylene glycol.
14 . The pharmaceutical composition of claim 1 , further comprising a crosslinked hydrophilic polymer.
15 . A delivery system for topical or transdermal administration of a pharmacologically active agent, comprising a laminated composite of:
a skin contact adhesive layer comprising the pharmaceutical composition of claim 1; and,
laminated thereto, a flexible backing material that serves as the outer surface of the system following application to a body surface.
16 . The delivery system of claim 15 , further including a removable release liner covering the skin contact adhesive layer prior to use, said release liner preventing exposure of the layer to air.
17 . The delivery system of claim 15 , wherein the flexible backing material is comprised of a hydrophobic polymer.
18 . The delivery system of claim 17 , wherein the flexible backing material is permeable.
19 . The delivery system of claim 15 , wherein the skin contact adhesive layer is bisected into two separate layers by a nonwoven layer.
20 . A packaged, anhydrous active agent delivery system, comprising the delivery system of claim 15 in a moisture-free sealed pouch.
21 . A conductive bioadhesive composition, comprising:
at least two water-swellable, water-insoluble polymers that in combination render the composition adhesive upon contact with moisture, wherein a first water-swellable, water-insoluble polymer is cationic, a second water-swellable, water-insoluble polymer is anionic, and the polymers are ionically associated with each other to form a polymer matrix; and
an amount of an ionically conductive electrolyte effective to render the composition electrically conductive.
22 . The conductive bioadhesive composition of claim 21 , wherein the ionically conductive electrolyte is selected from ionizable inorganic salts, organic compounds, and combinations thereof.
23 . A conductive bioadhesive composition of claim 21 , wherein the ionically conductive electrolyte is selected from ammonium sulfate, ammonium acetate, monoethanolamine acetate, diethanolamine acetate, sodium lactate, sodium citrate, magnesium acetate, magnesium sulfate, sodium acetate, calcium chloride, magnesium chloride, calcium sulfate, lithium chloride, lithium perchlorate, sodium citrate and potassium chloride, redox couples, potassium chloride, sodium chloride, magnesium sulfate, magnesium acetate, and combinations thereof.
24 . The conductive bioadhesive composition of claim 21 , wherein an electrolyte is present at a concentration in the range of about 0.1 to about 15 wt. % of the conductive bioadhesive.
25 . A wound dressing comprising a laminated composite of a body facing layer having a body-contacting surface, and an outwardly facing backing layer, wherein at least a portion of the body-contacting surface is composed of a water-swellable, water-insoluble polymer composition comprising at least two water-swellable, water-insoluble polymers that in combination render the composition adhesive upon contact with moisture, wherein a first water-swellable, water-insoluble polymer is cationic, a second water-swellable, water-insoluble polymer is anionic, and the polymers are ionically associated with each other to form a polymer matrix.
26 . The wound dressing of claim 25 , wherein the entire body-contacting surface is comprised of the water-swellable, water-insoluble polymer composition.
27 . The wound dressing of claim 26 , wherein the body-facing layer has a perimeter comprised of a skin-contact adhesive and an inner region containing the water-swellable, water-insoluble polymer composition.
28 . The wound dressing of claim 27 , wherein a central, wound-contacting portion of the inner region is comprised of the water-swellable, water-insoluble polymer composition.
29 . The wound dressing of claim 25 , wherein the backing layer is nonocclusive.
30 . The wound dressing of claim 25 , wherein the backing layer is occlusive.
31 . The wound dressing of claim 25 , further including a pressure-sensitive adhesive layer between the body-facing layer and the backing layer.
32 . The wound dressing of claim 25 , further including a removable release liner covering and co-extensive with the body-facing surface.
33 . The wound dressing of claim 25 , further including an active agent suitable for application to a wound.
34 . The wound dressing of claim 33 , wherein the active agent is selected from the group consisting of bacteriostatic and bactericidal compounds, antibiotic agents, pain relieving agents, topical vasodilators, tissue-healing enhancing agents, amino acids, proteins, proteolytic enzymes, cytokines, and polypeptide growth factors.